[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C][N][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][=N][C][=C][Branch1][=Branch2][C][C][C][C][C][C][Ring1][Branch2][C][=Branch1][Ring2][=C][Ring1][N][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][F]"}, {"from": "gpt", "value": "The molecule is an atypical antipsychotic approved in Japan in January, 2008. It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics."}]